NasdaqGS:DXCMMedical Equipment
A Look At Dexcom (DXCM) Valuation As Expanded Reimbursement Opens A New Type 2 Market
DexCom (DXCM) is back in focus after expanded insurance reimbursement opened a large new market for its continuous glucose monitoring systems, giving more type 2 non insulin patients access to its products.
See our latest analysis for DexCom.
Despite the reimbursement expansion opening up a fresh pool of type 2 non insulin users, DexCom’s recent share price performance has been weak, with a 30 day share price return of 7.88% and a 1 year total shareholder return of 14.08%, pointing to fading...